Lingmin Xu

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies

Nan Wang, Fei Li, Daihong Liu, 2022, Drug design, development and therapy.

Next-generation sequencing revealed factors associated with cumulative incidence of relapse and leukemia-free survival in patients with newly diagnosed acute myeloid leukemia

Nan Wang, Jing Chen, Shanbo Cao, 2022, Cancer Pathogenesis and Therapy.

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial

Daihong Liu, L. Dou, Fei Li, 2022, Trials.

High Risk of Recurrence of Malignancy Noted in 4-day rATG Regimen after Allogeneic PBSCT from Matched Sibling Donors.

Nan Wang, Haitao Wang, L. Dou, 2022, Transplantation and cellular therapy.

Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells

Guodong Yang, Li Liu, Xiaotong Gao, 2017, Molecular medicine reports.

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy

Daihong Liu, L. Dou, Xiang-shu Jin, 2021, Annals of Hematology.